These results suggest that a proactive prophylactic management of skin rash with a PD-based cream can reduce the incidence of grade ≥2 skin toxicities without additional side effects in patients treated with afatinib.

Afatinib-induced cutaneous toxicity has a positive correlation with tumor response to anti-neoplastic therapy. Supplemental systemic and topical treatments can be initiated to palliate adverse skin events in order to enable adequate duration of treatment with afatinib.

Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting. In this review, we describe clinical trial experience with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC.

Jan 22, 2014 · Therapeutic intervention involves appropriate skin care, sun protection, moisturizers, topical corticosteroids, and topical or systemic antibiotics. Pharmacists can play an important role in the identification and appropriate treatment of EGFR inhibitor–related skin rash.

Oct 1, 2006 · The most frequent reactions are: a papulopustular rash that affects the face and upper trunk; dry and itchy skin; inflammation around the nails, with or without brittle or deformed nails; loss of...

Nov 1, 2016 · Background: Afatinib as a second generation of epidermal grouth factor recepter (EGFR) tyrosine kinase inhibitor (TKI) occurs in side effects such as diarrhea, skin rash, oral mucosotis, and paronychia.

Jan 10, 2014 · Similar to EGFR inhibitors, dermatologic AEs have been frequently observed in patients treated with afatinib. Papulopustular (acneiform) rash, pruritus, xerosis, paronychia and alopecia will require patient education and proactive treatment interventions.

Jan 31, 2019 · Objective: This study evaluated the effect of topical application of a moisturizer containing PD to prevent skin rash in patients with mutated non-small cell lung cancer (NSCLC) treated with afatinib.

May 1, 2023 · Afatinib is an irreversible second-generation tyrosine kinase inhibitor. It is used to treat epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma. The most well-known side effects associated with afatinib are diarrhea, rashes or acne and stomatitis.

Grade 2 or higher skin rash might be a marker for long-term efficacy of afatinib when administered as a first-line treatment.